TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07816367: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Acute Treatment of Migraine

Sponsor: TriGemX Bio, Inc. · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 1500 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$14,986,112

Rescue Site Savings

+$9,917,280

Unlock Full NCT07816367 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07816367 Rescue Dossier →